Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P10644: Variant p.Arg74Cys

cAMP-dependent protein kinase type I-alpha regulatory subunit
Gene: PRKAR1A
Feedback?
Variant information Variant position: help 74 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Cysteine (C) at position 74 (R74C, p.Arg74Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 74 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 381 The length of the canonical sequence.
Location on the sequence: help FERLEKEEAKQIQNLQKAGT R TDSREDEISPPPPNPVVKGR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         FERLEKEEAKQIQNLQKAGTRTDSREDEISPPPP-NPVVKGR

Mouse                         FERLEKEEARQIQCLQKTGIRTDSREDEISPPPP-NPVVKG

Rat                           FERLEKEEARQIQSLQKSGIRTDSREDEISPPPP-NPVVKG

Pig                           FERLEKEEAKQIQNLQKASARADSREDEISPPPP-NPVVKG

Bovine                        FEKLEKEEAKQIQNLQKAGSRADSREDEISPPPP-NPVVKG

Chicken                       FERLEKEETKQLLNQQKSGSRSDSREDEISPPPPMNPVVKG

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 381 cAMP-dependent protein kinase type I-alpha regulatory subunit
Region 1 – 136 Dimerization and phosphorylation
Region 64 – 96 Disordered
Modified residue 75 – 75 Phosphothreonine
Modified residue 77 – 77 Phosphoserine
Modified residue 83 – 83 Phosphoserine



Literature citations
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice.
Veugelers M.; Wilkes D.; Burton K.; McDermott D.A.; Song Y.; Goldstein M.M.; La Perle K.; Vaughan C.J.; O'Hagan A.; Bennett K.R.; Meyer B.J.; Legius E.; Karttunen M.; Norio R.; Kaariainen H.; Lavyne M.; Neau J.-P.; Richter G.; Kirali K.; Farnsworth A.; Stapleton K.; Morelli P.; Takanashi Y.; Bamforth J.-S.; Eitelberger F.; Noszian I.; Manfroi W.; Powers J.; Mochizuki Y.; Imai T.; Ko G.T.C.; Driscoll D.A.; Goldmuntz E.; Edelberg J.M.; Collins A.; Eccles D.; Irvine A.D.; McKnight G.S.; Basson C.T.;
Proc. Natl. Acad. Sci. U.S.A. 101:14222-14227(2004)
Cited for: VARIANT CNC1 CYS-74; In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay.
Greene E.L.; Horvath A.D.; Nesterova M.; Giatzakis C.; Bossis I.; Stratakis C.A.;
Hum. Mutat. 29:633-639(2008)
Cited for: VARIANTS CNC1 ASN-9; SER-146; TYR-183; ASP-213 AND TRP-289; CHARACTERIZATION OF VARIANTS CNC1 ASN-9; CYS-74; SER-146; TYR-183; ASP-213 AND TRP-289;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.